Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

Expert Review of Anticancer Therapy

Volumn 10, Issue 10, 2010, Pages 1663-1672

  Heise, Carla ^a   Carter, Troy ^a   Schafer, Peter ^a   Chopra, Rajesh ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

chromosome 5; del(5q); lenalidomide; mechanism of action; myelodysplastic syndromes

Indexed keywords

ALPHA CATENIN; AURORA B KINASE; CITRON KINASE; COLONY STIMULATING FACTOR 1; EARLY GROWTH RESPONSE FACTOR; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; F ACTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE H3; INTERCELLULAR ADHESION MOLECULE 1; KINESIN; LENALIDOMIDE; LYSINE SPECIFIC DEMETHYLASE 1; METHENAMINE; METHYLTRANSFERASE; MICRORNA; MYOSIN HEAVY CHAIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; PROTEIN; PROTEIN P53; PROTEIN SPARC; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIVISION; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROPOIESIS; GENE DELETION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOMODULATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PLEIOTROPY; REVIEW; STEM CELL; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; ERYTHROPOIESIS; GENES; HUMANS; IMMUNOLOGIC FACTORS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77958050048     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.135     Document Type: Review

References (61)

1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109(8), 1536-1542 (2007). (Pubitemid 46595689)
2. Greenberg P, Cox C, LeBeau M et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079-2088 (1997).
3. Hellstrom-Lindberg E. Myelodysplastic Syndromes. Remedica Pub. Ltd, London, UK (2008).
4. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51(2), 189-199 (1982).
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7), 2292-2302 (2002).
6. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5), 937-951 (2009).
7. Kantarjian H, O'Brien S, Ravandi F et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 115(22), 5202-5209 (2009).
8. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl J. Med. 355(14), 1456-1465 (2006).
9. Fenaux P, Giagounidis A, Selleslag D et al. RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in pts with low- or int-1-risk MDS with del5q: results from a randomized Phase III trial (MDS-004). Blood 114(11) (2009) (Abstract 944).
10. Adès L, Boehrer S, Prebet T et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a Phase 2 study. Blood 113(17), 3847-3952 (2009).
11. Göhring G, Giagounidis A, Büsche G et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann. Hematol. 89(4), 365-374 (2009).
12. Jädersten M, Saft L, Pellagatti A et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94(12), 1762-1766 (2009).
13. Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 23(7), 1252-1256 (2009).
14. Fodde R, Smits R. Cancer biology. A matter of dosage. Science 298(5594), 761-763 (2002).
15. Foulkes WD. Inherited susceptibility to common cancers. N. Engl. J. Med. 359(20), 2143-2153 (2008).
16. Eisenmann KM, Dykema KJ, Matheson SF et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 28(39), 3429-3441 (2009).
17. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin. Cancer Res. 12(1), 5-10 (2006).
18. Graubert TA, Payton MA, Shao J et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 4(2), e4583 (2009).
19. Bernasconi P, Boni M, Cavigliano PM et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann. N. Y. Acad. Sci. 1089, 395-410 (2006).
20. Boultwood J, Fidler C, Strickson AJ et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99(12), 4638-4641 (2002).
21. Ebert BL, Pretz J, Bosco J et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451(7176), 335-339 (2008).
22. Starczynowski DT, Kuchenbauer F, Argiropoulos B et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 16(1), 49-58 (2010).
23. Horrigan SK, Arbieva ZH, Xie HY et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 95(7), 2372-2377 (2000).
24. Barlow JL, Drynan LF, Hewett DR et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med. 16(1), 59-66 (2010).
25. DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related formin mDia1 knockout mice. PLoS One 4(9), e7102 (2009).
26. Escoubet-Lozach L, Lin IL, Jensen- Pergakes K et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 69(18), 7347-7356 (2009).
27. Verhelle D, Corral LG, Wong K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 67(2), 746-755 (2007).
28. Zhang LH, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. Blood 112(11) (2008) (Abstract 2612).
29. Wei S, Chen X, Rocha K et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc. Natl Acad. Sci. USA 106(31), 12974-12979 (2009).
30. Gaidarova S, Corral LG, Gleizer E et al. Lenalidomide enhances anti-tumor effect of gd T cells against mantle cell lymphoma. Blood 112(11) (2008) (Abstract 2616).
31. Ramsay AG, Johnson AJ, Lee AM et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118(7), 2427-2437 (2008).
32. Xu Y, Li J, Ferguson GD et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114(2), 338-345 (2009).
33. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk. Res. 30(7), 849-858 (2006).
34. Pellagatti A, Jädersten M, Forsblom AM et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl Acad. Sci. USA 104(27), 11406-11411 (2007).
35. Ximeri M, Galanopoulos A, Klaus M et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndromes associated with chromosome 5q deletion. Haematologica 95(3), 406-414 (2010).
36. Barker TH, Baneyx G, Cardó-Vila M et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 280(43), 36483-36493 (2005).
37. Chlenski A, Liu S, Guerrero LJ et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int. J. Cancer 118(2), 310-316 (2006).
38. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J. Cell Biochem. 92(4), 679-690 (2004).
39. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 21(9), 1931-1936 (2007).
40. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor EGR1 is a direct regulator of multiple tumor suppressors including TGFb1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13(2), 115-124 (2006).
41. Min IM, Pietramaggiori G, Kim FS, Passegué E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2(4), 380-391 (2008).
42. Gandhi AK, Kang J, Verhelle D et al. Inhibition of cell proliferation by lenalidomide is associated with stimulation of Egr1 transcriptional activity in a chromosome 5 deleted Burkitt's lymphoma and multiple myeloma cell line. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 8110).
43. Matsuoka A, Tochigi A, Kishimoto M et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 24(4), 748-755 (2010).
44. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr. Cancer Drug Targets 10(2), 155-167 (2010).
45. Goode BL, Eck MJ. Mechanism and function of formins in the control of actin assembly. Annu. Rev. Biochem. 76, 593-627 (2007).
46. Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. Nat. Cell Biol. 9(10), 1110-1121 (2007).
47. Gaidarova S, Deyanat-Yazdi G, Bennett B, Lopez-Girona A. Lenalidomide affects F-actin cytoskeleton in mantle cell lymphoma cell in vitro. Presented at: 100th Annual Meeting of The American Association for Cancer Research. Denver, CO, USA, 18-22 April 2009 (Abstract 5236).
48. Eisenmann KM, West RA, Hildebrand D et al. T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice. J. Biol. Chem. 282(34), 25152-25158 (2007).
49. Moutouh-de Parseval LA, Verhelle D, Glezer E et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest. 118(1), 248-258 (2008).
50. Ebert BL, Galili N, Tamayo P et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 5(2), e35 (2008).
51. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol. 163(1), 380-386 (1999).
52. Schafer PH, Gandhi AK, Loveland MA et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther. 305(3), 1222-1232 (2003).
53. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57(12), 1849-1859 (2008).
54. Ramsay AG, Clear AJ, Kelly G et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114(21), 4713-4720 (2009).
55. Symeonidis A, Kourakli A, Katevas P et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur. J. Haematol. 47(4), 277-281 (1991).
56. Muller GW, Chen R, Huang SY et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-a production. Bioorg. Med. Chem. Lett. 9(11), 1625-1630 (1999).
57. Lu L, Payvandi F, Wu L et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res. 77(2), 78-86 (2009).
58. Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 87(10), 1166-1172 (2002).
59. Buesche G, Dieck S, Giagounidis A et al. Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood 106(11) (2005) (Abstract 372).
60. Buesche G, Dieck S, Giagounidis A et al. Anti-angiogenic in-vivo effect of lenalidomide and its impact on neoplastic and non-neoplastic hematopoiesis in MDS with del(5q) chromosome abnormality. Blood 114(11) (2009) (Abstract 3800).
61. Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res. 69(1-2), 56-63 (2005).